Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
- 1 July 2013
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 139 (1), 51-59
- https://doi.org/10.1016/j.pharmthera.2013.04.003
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on MetforminJournal of Clinical Endocrinology & Metabolism, 2012
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal ModelsPLOS ONE, 2012
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trialDiabetes, Obesity and Metabolism, 2011
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activityBritish Journal of Pharmacology, 2011
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal TubuleJournal of the American Society of Nephrology, 2011
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- The global burden of diabetes and its complications: an emerging pandemicEuropean Journal of Preventive Cardiology, 2010